Scientific | Philochem

Philogen receives authorisation to initiate new study in France to evaluate Nidlegy™ in several non-melanoma skin cancers

by mfantozzi | Feb 17, 2022 | 2022, Press Releases, Scientific

More details

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP)

by mfantozzi | Jan 7, 2022 | 2022, Press Releases, Scientific

More info here

Philogen announces new collaboration with Janssen to discover small molecule therapeutics

by mfantozzi | Nov 24, 2021 | 2021, Press Releases, Scientific

More datails

Philogen provides Corporate Update

by mfantozzi | Nov 12, 2021 | 2021, Press Releases, Scientific

Philogen to hold a Webinar at 11 am EST / 4 pm GMT / 5 pm CET on Friday 12th November 2021, Click here to view Press Release 12-11-2021

Philogen to attend the Cytokine-Based Cancer Immunotherapies Summit on November 30-December 2 , 2021

by mfantozzi | Nov 4, 2021 | 2021, Past Events, Scientific

Dario Neri, co-founder, CEO and CSO, is giving a presentation to address the question on how to achieve the therapeutic dose at the tumor site with cytokine-based targeted products. Roberto De Luca, Head of Antibody Therapeutics at Philogen, is also giving a...

Philogen announces Philochem Patent Upheld

by mfantozzi | Oct 15, 2021 | 2021, Press Releases, Scientific

Philogen announces that Philochem’s European Patent 3083957 relating to important features of proprietary DNA-encoded chemical libraries (“ESAC 2+1” technology) was upheld after Oral Proceedings in front of the Opposition Division at the European Patent Office. Read...